Tech Company Financing Transactions
Strand Therapeutics Funding Round
On 11/28/2022, Strand Therapeutics landed $45 million in Series A funding from FPV Ventures, Eli Lilly and Company and Playground Global.
Transaction Overview
Company Name
Announced On
11/28/2022
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to advance its first drug candidate, a programmable mRNA therapy for solid tumor immuno-oncology into Phase 1 clinical trials next year, to further develop its systemic delivery mechanism, which is designed to deliver tumor microenvironment-modifying mRNA to tumor sites and immune cells, and to expand its multidisciplinary team across biology, bioengineering, bioinformatics, manufacturing, automation, and various G&A functions.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
237 Putnam Ave.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
Strand was started by biological engineers working together at MIT. Building on the idea of creating smart therapies that are capable of making sophisticated decisions, they sought to apply the concept of the emerging field of mRNA therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jacob Becraft
Chief Operating Officer
Samta Kundu
Co-Founder
Darrell Irvine
Co-Founder
Ronald Weiss
President
Tasuku Kitada
Browse more venture capital transactions:
Prev: 11/28/2022: GWD venture capital transaction
Next: 11/28/2022: Escient Pharmaceuticals venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs